CAL103

CAL103 is a monoclonal antibody drug candidate under development by Calluna Pharma for the treatment of inflammatory and fibrotic diseases. It is part of a pipeline that includes other antibodies targeting pathways involved in inflammation and fibrosis. As of early 2024, CAL103 remains in the discovery or preclinical phase, with no detailed public information on its specific molecular target or mechanism beyond its categorization as an anti-inflammatory and antifibrotic monoclonal antibody[3][9]. The broader pipeline from Calluna Pharma focuses on neutralizing damage-associated molecular pattern (DAMP) proteins implicated in chronic inflammation and tissue damage.